Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.

Journal of neural transmission (Vienna, Austria : 1996) - 1 Mar 2015

Drago Antonio, Cocchi Enrico, Crisafulli Concetta, Serretti Alessandro

Abstract excerpt

The efficacy of current antidepressant (AD) drugs for the treatment of major depressive disorder (MDD) lays behind expectations. The correct genetic differentiation between severe and less severe cases before treatment may pave the way to the most correct clinical choices in clinical practice. Genetics may pave the way such identification, which in turns may provide perspectives for the synthesis of new ADs by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A Kinase Anchor Proteins
Share to Antidepressive Agents, Second-Generation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calcium-Calmodulin-Dependent Protein Kinase Type 2

Share to Citalopram

Share to Cyclic AMP

Share to Depressive Disorder, Major

Share to Linear Models

Share to Psychiatric Status Rating Scales

Source

Identifiers

PMID: 24986638
DOI: 10.1007/s00702-014-1267-2

Genes

AKAP12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.PMID 24986638Read ↗

The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes.Semantic proximity Read ↗

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.Semantic proximity Read ↗

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment.Semantic proximity Read ↗

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression RiskSemantic proximity Read ↗

Progress and prospects in pharmacogenetics of antidepressant drugsSemantic proximity Read ↗

The search for personalized antidepressant treatments: what have we learned and where are we going.Semantic proximity Read ↗

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.Semantic proximity Read ↗

Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned.Semantic proximity Read ↗

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.Semantic proximity Read ↗

Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.Semantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

Genetic variants in major depressive disorder: From pathophysiology to therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.